Sunday - May 4, 2025
DEERFIELD, Ill. / Jan 04, 2024 / Business Wire / Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its fourth-quarter 2023 financial results on Thursday, February 8, 2024 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://conferencingportals.com/event/etCeELhb to pre-register for the call and receive the call information.
This call is also being webcast and can be accessed through Baxter’s website at www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter’s permission.
About Baxter
Every day, millions of patients and caregivers rely on Baxter’s leading portfolio of diagnostic, critical care, kidney care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen. With products, digital health solutions and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com and follow us on Twitter, LinkedIn and Facebook.
Last Trade: | US$30.71 |
Daily Change: | 0.04 0.13 |
Daily Volume: | 4,082,096 |
Market Cap: | US$15.680B |
May 01, 2025 March 04, 2025 February 25, 2025 February 20, 2025 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load